Department of Otolaryngology, Massachusetts Eye and Ear, Boston, Massachusetts.
Department of Pediatric Pulmonary Medicine, Massachusetts General Hospital for Children, Boston, Massachusetts.
Pediatrics. 2024 May 1;153(5). doi: 10.1542/peds.2023-063330.
Obstructive sleep apnea (OSA) is common in children with Down syndrome (DS). Adenoidectomy and/or tonsillectomy are the usual first interventions employed to treat OSA in children with DS but sometimes do not achieve adequate resolution of clinical signs. Positive airway pressure treatment is often used next, but this treatment is poorly tolerated by this population. Persistent OSA can adversely affect a child's health and cognitive development. Hypoglossal nerve stimulation (HGNS), previously shown to be safe and effective in adults with OSA, has been used in children as young as 10 years old with DS and has achieved measurable neurocognitive benefits. The US Food and Drug Administration recently lowered the age for HGNS implantation to 13 years for children with DS. However, questions remain regarding treatment of refractory OSA in younger children. Here, we report the case of a 4-year-old boy with DS and treatment-refractory OSA who underwent successful HGNS implantation. The decision to proceed with HGNS implantation in such a young child involved discussions about anatomic feasibility and potential neurocognitive benefits. The device was implanted without complication and with minimal postoperative bulk. This case suggests a possible treatment option that can be discussed in the course of shared decision-making between clinicians and families of young children with DS and treatment-refractory OSA.
阻塞性睡眠呼吸暂停(OSA)在唐氏综合征(DS)患儿中较为常见。腺样体切除术和/或扁桃体切除术是治疗 DS 患儿 OSA 的常用初始干预措施,但有时并不能充分缓解临床症状。随后常采用气道正压治疗,但该方法在该人群中耐受性较差。持续的 OSA 会对儿童的健康和认知发育产生不良影响。舌下神经刺激(HGNS)先前已被证明在 OSA 成人患者中安全且有效,已被用于年龄最小为 10 岁的 DS 患儿,并取得了可衡量的神经认知益处。美国食品和药物管理局最近将 HGNS 植入的年龄下限降低至 13 岁,适用于 DS 患儿。然而,对于年龄较小的难治性 OSA 患儿的治疗仍存在疑问。在此,我们报告了一例 4 岁患有治疗抵抗性 OSA 的 DS 患儿,该患儿成功接受了 HGNS 植入术。决定对如此年幼的患儿进行 HGNS 植入术涉及到对解剖可行性和潜在神经认知益处的讨论。该设备无并发症地植入,术后体积最小。该病例提示了一种可能的治疗选择,可在临床医生和治疗抵抗性 OSA 的 DS 患儿的家庭之间进行共同决策时进行讨论。